| RS2137031313 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2137031805 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Familial cancer of breast |
| RS2137032635 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2137036897 |
POLR3B
|
Health Risk |
association |
Hypogonadotropic hypogonadism, Hypogonadotropic hypogonadism |
| RS2137040413 |
ATM
|
Health Risk |
Conflicting classifications of pathogenicity |
Ataxia-telangiectasia syndrome, Familial cancer of breast |
| RS2137042982 |
LRP6
|
Health Risk |
Likely pathogenic |
Autosomal dominant polycystic liver disease, Autosomal dominant polycystic liver disease |
| RS2137050478 |
CEP290
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Joubert syndrome |
| RS2137054010 |
PHC1
|
Health Risk |
Pathogenic |
Microcephaly 11, primary |
| RS2137056192 |
CEP290
|
Health Risk |
Pathogenic/Likely pathogenic |
CEP290-related disorder, Nephronophthisis |
| RS2137067282 |
CIT
|
Health Risk |
Pathogenic |
Microcephaly 17, primary |
| RS2137068260 |
ACBD5
|
Health Risk |
Likely pathogenic |
— |
| RS2137076976 |
FGD4
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 4, Charcot-Marie-Tooth disease type 4 |
| RS2137079086 |
ATM
|
Health Risk |
Conflicting classifications of pathogenicity |
Ataxia-telangiectasia syndrome, Hereditary cancer-predisposing syndrome |
| RS2137080156 |
CEP290
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Nephronophthisis |
| RS2137081192 |
PAK1
|
Health Risk |
Likely pathogenic |
Intellectual developmental disorder with macrocephaly, seizures |
| RS2137081530 |
PAK1
|
Health Risk |
Likely pathogenic |
Intellectual developmental disorder with macrocephaly, seizures |
| RS2137081759 |
PAK1
|
Health Risk |
Pathogenic |
Intellectual developmental disorder with macrocephaly, seizures |
| RS2137081902 |
PAK1
|
Health Risk |
Conflicting classifications of pathogenicity |
Intellectual developmental disorder with macrocephaly, seizures |
| RS2137082237 |
ATM
|
Health Risk |
Pathogenic |
Familial cancer of breast, Familial cancer of breast |
| RS2137082293 |
PAK1
|
Health Risk |
Pathogenic/Likely pathogenic |
Intellectual developmental disorder with macrocephaly, seizures |
| RS2137082609 |
PAK1
|
Health Risk |
Likely pathogenic |
Intellectual developmental disorder with macrocephaly, seizures |
| RS2137082728 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Hereditary cancer-predisposing syndrome |
| RS2137083265 |
ATM
|
Health Risk |
Likely pathogenic |
Breast and/or ovarian cancer, Breast and/or ovarian cancer |
| RS2137085814 |
ATM
|
Health Risk |
Pathogenic |
Ataxia-telangiectasia syndrome, Ataxia-telangiectasia syndrome |
| RS2137087134 |
ATM
|
Health Risk |
Pathogenic |
Familial cancer of breast, Papillary renal cell carcinoma type 1 |
| RS2137097782 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS2137101209 |
CEP290
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Nephronophthisis |
| RS2137103699 |
CEP290
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Joubert syndrome |
| RS2137106725 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137107185 |
ALG9
|
Health Risk |
Likely pathogenic |
Gillessen-Kaesbach-Nishimura syndrome, ALG9 congenital disorder of glycosylation |
| RS2137111897 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137112043 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137112309 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137112755 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137113019 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137115943 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137115961 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137116089 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137116356 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Abnormality of metabolism/homeostasis, Abnormality of metabolism/homeostasis |
| RS2137116390 |
GNPTAB
|
Health Risk |
Pathogenic |
Pseudo-Hurler polydystrophy, Mucolipidosis type II |
| RS2137116566 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137116678 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137116846 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137117072 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137117445 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137117586 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137117656 |
GNPTAB
|
Health Risk |
Pathogenic |
— |
| RS2137118051 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137119014 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS2137119084 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137119157 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137119177 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137119229 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137119323 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137121384 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137123723 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137123732 |
CTNND1
|
Health Risk |
Likely pathogenic |
— |
| RS2137123733 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137123738 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137124017 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137125146 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137126246 |
CTNND1
|
Health Risk |
Pathogenic |
Blepharocheilodontic syndrome 2, Blepharocheilodontic syndrome 2 |
| RS2137144428 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS2137148346 |
ABCC9
|
Health Risk |
Likely pathogenic |
Dilated cardiomyopathy 1O, Dilated cardiomyopathy 1O |
| RS2137150067 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137150220 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137150860 |
CEP290
|
Health Risk |
Pathogenic/Likely pathogenic |
Meckel-Gruber syndrome, Joubert syndrome |
| RS2137151163 |
CEP290
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Joubert syndrome |
| RS2137152484 |
CEP290
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Joubert syndrome |
| RS2137155220 |
TCF7L2
|
Health Risk |
Pathogenic |
Autism, Autism |
| RS2137155245 |
CEP290
|
Health Risk |
Pathogenic |
Meckel syndrome, type 4 |
| RS2137156392 |
CEP290
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Joubert syndrome |
| RS2137158804 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137165886 |
ABCC9
|
Health Risk |
Likely pathogenic |
Hypertrichotic osteochondrodysplasia Cantu type, Hypertrichotic osteochondrodysplasia Cantu type |
| RS2137167420 |
CEP290
|
Health Risk |
Likely pathogenic |
Nephronophthisis, Joubert syndrome |
| RS2137170285 |
CEP290
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Nephronophthisis |
| RS2137170380 |
CEP290
|
Health Risk |
Conflicting classifications of pathogenicity |
Retinitis pigmentosa, Leber congenital amaurosis 10 |
| RS2137174483 |
CEP83
|
Health Risk |
Pathogenic |
Nephronophthisis 18, Nephronophthisis 18 |
| RS2137178349 |
TCF7L2
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS2137178800 |
TCF7L2
|
Health Risk |
Likely pathogenic |
Neurodevelopmental abnormality, Neurodevelopmental abnormality |
| RS2137179429 |
TCF7L2
|
Health Risk |
Pathogenic |
— |
| RS2137182061 |
MED13L
|
Health Risk |
Likely pathogenic |
See cases, See cases |
| RS2137182509 |
CEP290
|
Health Risk |
Pathogenic/Likely pathogenic |
Meckel-Gruber syndrome, Joubert syndrome |
| RS2137183334 |
CEP290
|
Health Risk |
Pathogenic |
Nephronophthisis, Joubert syndrome |
| RS2137197827 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS2137216530 |
MED13L
|
Health Risk |
Pathogenic |
Cardiac anomalies - developmental delay - facial dysmorphism syndrome, Cardiac anomalies - developmental delay - facial dysmorphism syndrome |
| RS2137219551 |
CEP290
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Joubert syndrome |
| RS2137223723 |
MED13L
|
Health Risk |
Pathogenic |
Cardiac anomalies - developmental delay - facial dysmorphism syndrome, Cardiac anomalies - developmental delay - facial dysmorphism syndrome |
| RS2137238267 |
WBP11
|
Health Risk |
Likely pathogenic |
Vertebral, cardiac |
| RS2137241977 |
MED13L
|
Health Risk |
Likely pathogenic |
Cardiac anomalies - developmental delay - facial dysmorphism syndrome, Cardiac anomalies - developmental delay - facial dysmorphism syndrome |
| RS2137247685 |
CEP290
|
Health Risk |
Likely pathogenic |
Joubert syndrome, Meckel-Gruber syndrome |
| RS2137248487 |
CEP290
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Nephronophthisis |
| RS2137251821 |
CEP290
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Joubert syndrome |
| RS2137264830 |
MED13L
|
Health Risk |
Pathogenic |
Cardiac anomalies - developmental delay - facial dysmorphism syndrome, Cardiac anomalies - developmental delay - facial dysmorphism syndrome |
| RS2137269723 |
CEP290
|
Health Risk |
Pathogenic |
Meckel-Gruber syndrome, Nephronophthisis |
| RS2137272605 |
ABCC9
|
Health Risk |
Conflicting classifications of pathogenicity |
Hypertrichotic osteochondrodysplasia Cantu type, Dilated cardiomyopathy 1O |
| RS2137273654 |
MED13L
|
Health Risk |
Likely pathogenic |
— |
| RS2137274539 |
MED13L
|
Health Risk |
Likely pathogenic |
Cardiac anomalies - developmental delay - facial dysmorphism syndrome, Cardiac anomalies - developmental delay - facial dysmorphism syndrome |
| RS2137276301 |
CEP290
|
Health Risk |
Pathogenic/Likely pathogenic |
Meckel-Gruber syndrome, Joubert syndrome |
| RS2137277291 |
CEP290
|
Health Risk |
Pathogenic |
Nephronophthisis, Joubert syndrome |